Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AssigneeIDEC Pharmaceuticals Corporation
InventorsDarrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
Claims10
An improved method of treating B cell lymphoma which comprises administration of a therapeutic anti-CD20 antibody, wherein the improvement comprises administering at least one chemotherapeutic agent.
Dependencies are inferred from the claim text.